Endologix, Inc. (NASDAQ:ELGX) Given a $6.00 Price Target by Stifel Nicolaus Analysts

Stifel Nicolaus set a $6.00 price target on Endologix, Inc. (NASDAQ:ELGX) in a report published on Friday, October 6th. The brokerage currently has a hold rating on the medical instruments supplier’s stock.

Several other equities research analysts have also issued reports on the stock. Royal Bank Of Canada reissued a hold rating and issued a $5.00 target price on shares of Endologix in a report on Tuesday, October 3rd. Canaccord Genuity reissued a hold rating and issued a $5.00 target price on shares of Endologix in a report on Wednesday, September 27th. ValuEngine lowered shares of Endologix from a sell rating to a strong sell rating in a report on Friday, September 1st. BidaskClub downgraded Endologix from a hold rating to a sell rating in a research note on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. set a $5.00 price target on Endologix and gave the stock a hold rating in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating and eleven have assigned a hold rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $6.28.

Endologix (NASDAQ:ELGX) opened at 5.06 on Friday. Endologix has a 12 month low of $4.08 and a 12 month high of $12.74. The company’s market capitalization is $422.18 million. The stock’s 50 day moving average is $4.68 and its 200-day moving average is $5.26.

Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. Endologix had a negative net margin of 40.77% and a negative return on equity of 46.32%. The firm had revenue of $48.60 million during the quarter, compared to analyst estimates of $47.58 million. During the same quarter in the prior year, the firm earned ($0.20) EPS. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. On average, analysts expect that Endologix will post ($0.62) EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was first published by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://baseballnewssource.com/markets/endologix-inc-elgx-given-a-6-00-price-target-by-stifel-nicolaus-analysts/1697593.html.

Several institutional investors have recently made changes to their positions in ELGX. Redmile Group LLC increased its stake in shares of Endologix by 134.4% during the second quarter. Redmile Group LLC now owns 6,368,299 shares of the medical instruments supplier’s stock valued at $30,950,000 after buying an additional 3,650,905 shares during the period. Camber Capital Management LLC increased its stake in shares of Endologix by 65.1% during the first quarter. Camber Capital Management LLC now owns 6,000,000 shares of the medical instruments supplier’s stock valued at $43,440,000 after buying an additional 2,365,000 shares during the period. Point72 Asset Management L.P. increased its stake in shares of Endologix by 17,682.9% during the first quarter. Point72 Asset Management L.P. now owns 622,400 shares of the medical instruments supplier’s stock valued at $4,506,000 after buying an additional 618,900 shares during the period. TimesSquare Capital Management LLC increased its stake in shares of Endologix by 10.8% during the first quarter. TimesSquare Capital Management LLC now owns 3,814,670 shares of the medical instruments supplier’s stock valued at $27,618,000 after buying an additional 371,885 shares during the period. Finally, Vanguard Group Inc. increased its stake in shares of Endologix by 5.6% during the second quarter. Vanguard Group Inc. now owns 6,638,302 shares of the medical instruments supplier’s stock valued at $32,262,000 after buying an additional 353,233 shares during the period.

Endologix Company Profile

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Analyst Recommendations for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.